Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral...

Area of Science:

• Hepatology
• Virology
• Genetics

Background:

• Direct-acting antivirals (DAAs) offer high cure rates for Hepatitis C Virus (HCV).
• Certain patient groups, including those with cirrhosis or HCV genotype 3, present treatment challenges.
• The BOSON trial indicated a ~50% sustained virological response (SVR) rate for genotype 3 patients with cirrhosis on a 16-week DAA regimen.

Purpose of the Study:

• To investigate host genetic factors influencing treatment outcomes in HCV genotype 3 patients with cirrhosis.
• To explore the relationship between interferon lambda 4 (IFNL4) genotype and sustained virological response (SVR).
• To analyze the dynamic changes in interferon-stimulated gene (ISG) expression during DAA therapy in relation to host genotype.

Main Methods:

• Analysis of data from the BOSON trial, focusing on patients with HCV genotype 3 and cirrhosis.
• Genotyping for IFNL4 polymorphisms (CC vs. non-CC).
• Measurement of ISG signature in peripheral blood and liver tissue at baseline and during DAA treatment.

Main Results:

• The IFNL4 CC genotype was significantly associated with higher SVR rates in cirrhotic patients with HCV genotype 3.
• Patients with the IFNL4 CC genotype exhibited a lower baseline ISG signature.
• A dynamic increase in ISG expression was observed in CC genotype patients between weeks 4 and 16 of DAA therapy, unlike non-CC patients.

Conclusions:

• Host IFNL4 genotype plays a crucial role in modulating the host response to DAA therapy in HCV.
• The findings highlight a dynamic interplay between host genetic factors and virologic response during HCV treatment.
• These insights may also be relevant for understanding naturally acquired HCV infections and developing personalized treatment strategies.